Albireo to Present at Investor Conferences in June
May 29 2019 - 7:30AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced that Ron Cooper, President and
Chief Executive Officer, will present at the following investor
conferences in June:
2019 Jefferies Global Healthcare
ConferenceLocation: New York CityPresentation date / time:
Tuesday, June 4, 8 a.m. EDT
William Blair 39th Annual Growth Stock
ConferenceLocation: ChicagoPresentation date / time:
Thursday, June 6, 12 p.m. CDT
Live audio webcasts of both conference presentations will be
accessible from the Media & Investors page of Albireo’s
website, ir.albireopharma.com. To ensure a timely connection
to the webcasts, it is recommended that users register at least 15
minutes prior to the scheduled start time. An archived version of
the webcasts will be available for replay in the Events &
Presentations section of the Media & Investors page of
Albireo’s website for at least two weeks following each event.
About Albireo Albireo Pharma is a
clinical-stage biopharmaceutical company focused through its
operating subsidiary on the development of novel bile acid
modulators to treat orphan pediatric liver diseases, and other
liver and gastrointestinal diseases and disorders. Albireo’s lead
product candidate, odevixibat (A4250), is being developed to treat
rare pediatric cholestatic liver diseases and is in Phase 3
development in its initial target indication, progressive familial
intrahepatic cholestasis (PFIC). Albireo’s clinical pipeline also
includes two Phase 2 product candidates. Albireo’s elobixibat,
approved in Japan for the treatment of chronic
constipation, is the first ileal bile acid transporter (IBAT)
inhibitor approved anywhere in the world. Albireo was spun out
from AstraZeneca in 2008.
Albireo Pharma is located
in Boston, Massachusetts, and its key operating
subsidiary is located in Gothenburg, Sweden. The Boston
Business Journal named Albireo one of the 2019 Best Places to Work
in Massachusetts. For more information on Albireo, please
visit www.albireopharma.com.
Investor Contact: Hans Vitzthum, LifeSci
Advisors, LLC, 212-915-2568Media Contact: Heather
Anderson, 6 Degrees, 980-938-0260, handerson@6degreespr.com
Source: Albireo Pharma, Inc.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Sep 2023 to Sep 2024